Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Seeman

Showing results (241-250 of 325) with videos related to

Pageof 33
Sort By:
Neurology|August 25, 2004
Hearing loss as the first feature of late-onset axonal CMT disease due to a novel P0 mutationP Seeman, R Mazanec, K Huehne, et al.
Archives of Neurology|October 1, 1982
Reversible drug-induced parkinsonism. Clinicopathologic study of two casesA H Rajput, B Rozdilsky, O Hornykiewicz, et al.
Brain Research|May 18, 1981
Parkinson's disease: low density and presynaptic location of D3 dopamine receptorsT Lee, P Seeman, O Hornykiewicz, et al.
Archives of General Psychiatry|June 6, 2000
A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancyS Kapur, R Zipursky, C Jones, et al.
Neurogenetics|August 6, 2013
Mosaicism for GJB1 mutation causes milder Charcot-Marie-Tooth X1 phenotype in a heterozygous man than in a manifesting heterozygous womanI Borgulová, R Mazanec, I Sakmaryová, et al.
Molecular Pharmacology|July 1, 1983
Molecular size of the canine and human brain D2 dopamine receptor as determined by radiation inactivationL Lilly, C M Fraser, C Y Jung, et al.
Acta Psychiatrica Scandinavica|March 11, 2004
Does nicotine affect D2 receptor upregulation? A case-control studyS Silvestri, J C Negrete, M V Seeman, et al.
Journal of Psychopharmacology (Oxford, England)|January 1, 1997
Role of dopamine D2, D4 and serotonin(2A) receptors in antipsychotic and anticataleptic actionP Seeman, T Tallerico, R Corbett, et al.
Journal of Medicinal Chemistry|December 1, 1991
(+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationshipJ L Neumeyer, N Baindur, H B Niznik, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|June 1, 1985
Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2H B Niznik, D E Grigoriadis, I Pri-Bar, et al.
Pageof 33

Showing results (241-250 of 325) with videos related to

Sort By:
Pageof 33
Neurology|August 25, 2004
Hearing loss as the first feature of late-onset axonal CMT disease due to a novel P0 mutationP Seeman, R Mazanec, K Huehne, et al.
Archives of Neurology|October 1, 1982
Reversible drug-induced parkinsonism. Clinicopathologic study of two casesA H Rajput, B Rozdilsky, O Hornykiewicz, et al.
Brain Research|May 18, 1981
Parkinson's disease: low density and presynaptic location of D3 dopamine receptorsT Lee, P Seeman, O Hornykiewicz, et al.
Archives of General Psychiatry|June 6, 2000
A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancyS Kapur, R Zipursky, C Jones, et al.
Neurogenetics|August 6, 2013
Mosaicism for GJB1 mutation causes milder Charcot-Marie-Tooth X1 phenotype in a heterozygous man than in a manifesting heterozygous womanI Borgulová, R Mazanec, I Sakmaryová, et al.
Molecular Pharmacology|July 1, 1983
Molecular size of the canine and human brain D2 dopamine receptor as determined by radiation inactivationL Lilly, C M Fraser, C Y Jung, et al.
Acta Psychiatrica Scandinavica|March 11, 2004
Does nicotine affect D2 receptor upregulation? A case-control studyS Silvestri, J C Negrete, M V Seeman, et al.
Journal of Psychopharmacology (Oxford, England)|January 1, 1997
Role of dopamine D2, D4 and serotonin(2A) receptors in antipsychotic and anticataleptic actionP Seeman, T Tallerico, R Corbett, et al.
Journal of Medicinal Chemistry|December 1, 1991
(+/-)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3- benzazepin, a new high-affinity D1 dopamine receptor ligand: synthesis and structure-activity relationshipJ L Neumeyer, N Baindur, H B Niznik, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|June 1, 1985
Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2H B Niznik, D E Grigoriadis, I Pri-Bar, et al.
Pageof 33